{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer%2C+Advanced&page=18", "query": { "condition": "Cancer, Advanced", "page": 18 }, "page_size": 10 }, "pagination": { "page": 18, "page_size": 10, "total_count": 9813, "total_pages": 982, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer%2C+Advanced&page=19&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer%2C+Advanced&page=17&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-07T08:29:53.067Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02925000", "title": "Dose-escalation Study of Intravenous Liposomal Vinorelbine Tartrate Injection in Patients With Advanced Malignancy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "TLC178", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Taiwan Liposome Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2017-06-19", "completion_date": "2020-10-06", "has_results": false, "last_update_posted_date": "2021-07-23", "last_synced_at": "2026-11-07T08:29:53.067Z", "location_count": 2, "location_summary": "Detroit, Michigan • The Bronx, New York", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02925000" }, { "nct_id": "NCT00325507", "title": "Safety and Biological Activity of TroVax® Vaccine Given With IL-2 in Renal Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Renal Cell" ], "interventions": [ { "name": "TroVax", "type": "BIOLOGICAL" }, { "name": "IL-2", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Oxford BioMedica", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2005-11", "completion_date": "2008-07", "has_results": false, "last_update_posted_date": "2020-10-19", "last_synced_at": "2026-11-07T08:29:53.067Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00325507" }, { "nct_id": "NCT00347412", "title": "Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" }, { "name": "NOV-002", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cellectar Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 903, "start_date": "2006-11", "completion_date": "2010-02", "has_results": false, "last_update_posted_date": "2022-07-25", "last_synced_at": "2026-11-07T08:29:53.067Z", "location_count": 12, "location_summary": "Muscle Shoals, Alabama • San Diego, California • Chicago, Illinois + 9 more", "locations": [ { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "San Diego", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "South Bend", "state": "Indiana" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00347412" }, { "nct_id": "NCT03631407", "title": "Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Neoplasms" ], "interventions": [ { "name": "Vicriviroc", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2018-09-24", "completion_date": "2021-06-08", "has_results": true, "last_update_posted_date": "2024-11-21", "last_synced_at": "2026-11-07T08:29:53.067Z", "location_count": 6, "location_summary": "Scottsdale, Arizona • Encinitas, California • Fresno, California + 3 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Encinitas", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03631407" }, { "nct_id": "NCT02003092", "title": "RX-5902 Treatment of Subjects With Triple Negative Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor", "Triple Negative Breast Cancer" ], "interventions": [ { "name": "RX-5902", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rexahn Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2013-08", "completion_date": "2019-11", "has_results": false, "last_update_posted_date": "2020-01-06", "last_synced_at": "2026-11-07T08:29:53.067Z", "location_count": 8, "location_summary": "Tucson, Arizona • Aurora, Colorado • Chicago, Illinois + 5 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT02003092" }, { "nct_id": "NCT01023737", "title": "Hydroxychloroquine + Vorinostat in Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Solid Tumour" ], "interventions": [ { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Vorinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The University of Texas Health Science Center at San Antonio", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 72, "start_date": "2009-11", "completion_date": "2023-01-08", "has_results": false, "last_update_posted_date": "2023-02-13", "last_synced_at": "2026-11-07T08:29:53.067Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01023737" }, { "nct_id": "NCT01697072", "title": "First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastric Cancer" ], "interventions": [ { "name": "Rilotumumab", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Epirubicin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 609, "start_date": "2012-10", "completion_date": "2015-08", "has_results": false, "last_update_posted_date": "2016-02-09", "last_synced_at": "2026-11-07T08:29:53.067Z", "location_count": 16, "location_summary": "Tucson, Arizona • Aurora, Colorado • Pueblo, Colorado + 13 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Pueblo", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01697072" }, { "nct_id": "NCT07580339", "title": "Combining DCSZ11 With Radiation and Chemotherapy as Neoadjuvant Treatment for pMMR Locally Advanced Rectal Cancer", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rectal Cancer" ], "interventions": [ { "name": "DCSZ11", "type": "DRUG" }, { "name": "Radiation", "type": "RADIATION" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2026-11", "completion_date": "2030-11", "has_results": false, "last_update_posted_date": "2026-10-28", "last_synced_at": "2026-11-07T08:29:53.067Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07580339" }, { "nct_id": "NCT02718911", "title": "A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "LY3022855", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Tremelimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2016-06-16", "completion_date": "2018-12-14", "has_results": true, "last_update_posted_date": "2023-10-16", "last_synced_at": "2026-11-07T08:29:53.067Z", "location_count": 7, "location_summary": "Denver, Colorado • Sarasota, Florida • Atlanta, Georgia + 2 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02718911" }, { "nct_id": "NCT02586207", "title": "Pembrolizumab in Combination With CRT for LA-SCCHN", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Cancer", "Squamous Cell Carcinoma", "Oral Cavity Cancer", "Oropharynx Cancer", "Hypopharynx Cancer", "Larynx Cancer", "Laryngeal Cancer" ], "interventions": [ { "name": "pembrolizumab (MK-3475)", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Radiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Sanford Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 59, "start_date": "2015-11", "completion_date": "2025-08", "has_results": true, "last_update_posted_date": "2025-10-07", "last_synced_at": "2026-11-07T08:29:53.067Z", "location_count": 4, "location_summary": "La Jolla, California • Bismarck, North Dakota • Fargo, North Dakota + 1 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Bismarck", "state": "North Dakota" }, { "city": "Fargo", "state": "North Dakota" }, { "city": "Sioux Falls", "state": "South Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02586207" } ] }